研究目的
To develop a dedicated platform for multiparametric exosome analysis through simultaneous biophysical and biomolecular evaluation of the same vesicles directly in clinical biofluids.
研究成果
The TPEX platform enables rapid, sensitive, and wash-free multiparametric analysis of exosomal biomarkers directly in clinical samples. It distinguishes biomarker organizational states and shows that the exosomal subpopulation could more accurately differentiate patient prognosis.
研究不足
The technology requires further validation in large-scale clinical studies across a spectrum of diseases. Technical improvements could enhance the analytical performance to measure rare and complex molecular modifications.
1:Experimental Design and Method Selection:
The TPEX platform was designed to distinguish and measure exosomal markers from nonvesicle, free molecules through three functional steps: double labeling, development of templated nanoplasmonics, and signal detection.
2:Sample Selection and Data Sources:
Exosomes derived from human colorectal adenocarcinoma cell line (DLD-1) and other cell lines were used. Clinical ascites samples from cancer patients were also analyzed.
3:List of Experimental Equipment and Materials:
Transmission electron microscopy (TEM), dynamic light scattering analysis, microfluidic device, smartphone-based optical detector, gold nanoparticles (AuNP), fluorescent aptamers, and antibodies.
4:Experimental Procedures and Operational Workflow:
Exosomes were labeled with fluorescent molecular probes and AuNP, followed by in situ gold growth to form nanoshells. The resultant optical signals (absorbance and fluorescence) were measured.
5:Data Analysis Methods:
TPEX absorbance and fluorescence measurements were defined and analyzed to evaluate exosomal biomarkers.
独家科研数据包,助您复现前沿成果,加速创新突破
获取完整内容